REFERENCES
1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
2. Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observation al study of lipid-modifying therapy use in sec ondary and pri mary care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279-89.
3. Chi G, Lee JJ, Kazmi SHA, et al. Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. Clin Cardiol 2022;45:299-307.
4. Rao SV, O’donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2025;151:e771-862.
5. Mehta SR, Pare G, Lonn EM, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention 2022;18:e888-96.
6. Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022;327:1771.
7. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 2014;76:39-56.
8. Ball AT, Mohammed S, Doigneaux C, et al. Identification and development of cyclic peptide inhibitors of hypoxia inducible factors 1 and 2 that disrupt hypoxia-response signaling in cancer cells. J Am Chem Soc 2024;146:8877-86.
9. Ning L, Zou Y, Li S, et al. Anti-PCSK9 treatment attenuates liver fibrosis via inhibiting hypoxia-induced autophagy in hepatocytes. Inflammation 2023;46:2102-19.
10. Zhang Y, Liu J, Li S, et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord 2014;14:192.
11. Ma C, Liu Y, Fu Z. Implications of endoplasmic reticulum stress and autophagy in aging and cardiovascular diseases. Front Pharmacol 2024;15:1413853.
12. Lebeau P, Al-Hashimi A, Sood S, et al. Endoplasmic reticulum stress and Ca2+ depletion differentially modulate the sterol regulatory protein PCSK9 to control lipid metabolism. J Biol Chem 2017;292:1510-23.
13. Ruscica M, Ricci C, Macchi C, et al. Suppressor of cytokine signaling-3 (SOCS-3) Induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem 2016;291:3508-19.
14. Tang Z, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis 2017;262:113-22.
15. Li H, Dong B, Park SW, Lee H, Chen W, Liu J. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95.
16. Duddu S, Katakia YT, Chakrabarti R, Sharma P, Shukla PC. New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia. J Lipid Res 2025;66:100699.
17. Ben Djoudi Ouadda A, Gauthier M, Susan-Resiga D, et al. Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor). Arterioscler Thromb Vasc Biol 2019;39:1996-2013.
18. Zhang X, Hao Y, Han D, et al. PRMT3-mediated arginine methylation stabilizes PCSK9 to promote aortic valve calcification. Circulation 2026;153:1637-60.
19. Ding Z, Liu S, Wang X, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal 2015;22:760-71.
20. Huang L, Li Y, Cheng Z, Lv Z, Luo S, Xia Y. PCSK9 promotes endothelial dysfunction during sepsis via the TLR4/MyD88/NF-κB and NLRP3 pathways. Inflammation 2022;46:115-28.
21. Wang F, Li M, Zhang A, Li H, Jiang C, Guo J. PCSK9 modulates macrophage polarization-mediated ventricular remodeling after myocardial infarction. J Immunol Res 2022;2022:1-18.
22. Wang C, Zhang W, Liu Y, Guo Y. Targeting PCSK9 suppresses NF-κB-mediated M1 polarization in alveolar macrophages and lung injury induced by low-dose systemic PM2.5 exposure. Toxicol Lett 2026;419:111887.
23. Wang X, Li X, Liu S, et al. PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia. Basic Res Cardiol 2020;115:66.
24. Espadas C, Soto-Catalán M, Romero-Cote M, et al. Alirocumab attenuated plaque inflammation and PCSK9-induced proinflammatory signalling in M1 macrophages independently of lipid lowering. Biomolecules 2026;16:397.
25. Qi Z, Hu L, Zhang J, et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation 2021;143:45-61.
26. Cammisotto V, Pastori D, Nocella C, et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation. Antioxidants 2020;9:296.
27. Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacol Res 2022;184:106439.
28. Laudette M, Lindbom M, Arif M, et al. Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovasc Res 2023;119:1537-52.
29. Laudette M, Lindbom M, Cinato M, et al. PCSK9 regulates cardiac mitochondrial cholesterol by promoting TSPO degradation. Circ Res 2025;136:924-42.
30. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 2013;22:399-411.
31. Biccirè FG, Gatto L, La Porta Y, Pignatelli P, Prati F, Pastori D. Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature. J Cardiovasc Dev Dis 2023;10:260.
32. Kataoka T, Morishita T, Uzui H, et al. Very short-term effects of a single dose of a proprotein convertase subtilisin/kexin 9 inhibitor before percutaneous coronary intervention: A single-arm study. Atherosclerosis 2024;399:118581.
33. Fujimoto D, Fuster V, Jang I. The sequence of changes in intravascular imaging findings during lipid-lowering therapy and its implication. Nat Cardiovasc Res 2025;4:661-76.
34. Barbieri L, Tumminello G, Fichtner I, et al. PCSK9 and coronary artery plaque—new opportunity or red herring? Curr Atheroscler Rep 2024;26:589-602.
35. Li Z, Guo L, An Y, et al. Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes. Basic Res Cardiol 2025;120:301-20.
36. Zhang M, Liu F, Gao Y, et al. PCSK9 inhibition protects against myocardial ischemia-reperfusion injury in type 2 diabetes rats via suppressing inflammation and apoptosis. Anatol J Cardiol 2025;30:146-56.
37. Huang Q, Zhou Z, Xu L, Zhan P, Huang G. PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway. Biochem Pharmacol 2024;230:116563.
38. An H, Zhu J, Li Q. PCSK9 inhibitor improved cardiac function after acute myocardial infarction in rats. Microvasc Res 2025;162:104847.
39. Puteri MU, Azmi NU, Kato M, Saputri FC. PCSK9 promotes cardiovascular diseases: recent evidence about its association with platelet activation-induced myocardial infarction. Life 2022;12:190.
40. Jin P, Ma J, Wu P, et al. PCSK9 inhibition mitigates vulnerable plaque formation induced by hyperhomocysteinemia through regulating lipid metabolism and inflammation. Biochem Pharmacol 2025;239:117031.
41. Cebova M, Bulkova R, Pechanova O. Evolocumab reduces oxidative stress and lipid peroxidation in obese zucker rats. Pathophysiology 2025;32:5.
42. Zulkapli R, Muid SA, Wang SM, Putera Mohd Yusof MY, Nawawi H. Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells. BMC Cardiovasc Disord 2025;25:537.
43. Desouky MA, El-Magd MA, Mousa MA, Mallick AH, Khan D, Desouky DA. PCSK9 molecular bridge between hyperlipidemia and vascular inflammation: novel insights into PCSK9-centered pathways in atherosclerosis: a comprehensive review. Beni-Suef Univ J Basic Appl Sci 2025;14:105.
44. Leucker T, Amat-Codina N, Chelko S, Gerstenblith G. Proprotein convertase subtilisin/kexin type 9 links inflammation to vascular endothelial cell dysfunction. Eur Heart J 2021;42:ehab724.3436.
45. D’onofrio N, Donisi I, Del Vecchio V, et al. PCSK9 inhibition ameliorates microplastic-induced endothelial redox imbalance via SIRT6 modulation. Cell Mol Biol Lett 2025;31:9.
46. Wang P, Wang H, Yan D, Zhang Z. Endothelial cell-derived PCSK9 in atherosclerosis: pathophysiological roles and therapeutic perspectives. Rev Cardiovasc Med 2025;26:44885.
47. Itzhaki Ben Zadok O, Mager A, Leshem-Lev D, Lev V, Kornowski R, Eisen A. The effect of proprotein convertase subtilisin kexin type 9 inhibitors on circulating endothelial progenitor cells in patients with cardiovascular disease. Cardiovasc Drugs Ther 2021;36:85-92.
48. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
49. Gim DH, Choi IY, Ki Y, et al. Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome. Korean J Intern Med 2025;40:438-48.
50. Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol 2019;74:2452-62.
51. Trankle CR, Wohlford G, Buckley LF, et al. Alirocumab in acute myocardial infarction: results from the virginia commonwealth university alirocumab response trial (VCU-AlirocRT). J Cardiovasc Pharmacol 2019;74:266-9.
52. Knowlton KU, Navar AM, Anderson JL, et al. Low-density lipoprotein cholesterol lowering with inclisiran plus usual care in recent acute coronary syndrome: VICTORION-INCEPTION, a randomized, controlled, open-label trial. J Am Heart Assoc 2026;15:e043655.
53. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097-107.
54. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-19.
55. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556.
56. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071.
57. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol 2014;64:2207-17.
58. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging 2022;15:1308-21.
59. Ziogos E, Harb T, Valenta I, et al. Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial. JACC Basic Transl Sci 2025;10:709-20.
60. Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol 2020;5:952.
61. Ray KK, Szarek M, Bhatt DL, et al. Lipoprotein(a) levels and time to cardiovascular benefit with alirocumab in patients with recent acute coronary syndrome. J Am Coll Cardiol 2025;86:2071-6.
62. Khatib R, Yeh EJ, Glowacki N, et al. Lipid-lowering therapy utilization and dosage among patients with acute coronary syndrome events: a retrospective cohort from 12 community hospitals. Clin Epidemiol 2023;15:547-57.
63. Gargiulo P, Basile C, Galasso G, et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol 2024;31:1806-16.
64. Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY. Adherence to PCSK9 inhibitors in clinical practice : systematic review and meta-analysis of observational studies. JACC Adv 2026;5:102733.
65. Hosseini K, Soleimani H, Maleki S, et al. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord 2024;24:395.
66. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med 2019;170:221-9.
67. Xi X, Wang X, Xie W, et al. Comparison of evolocumab and ezetimibe, both combined with statin therapy, for patients with recent acute coronary syndrome: a cost-effectiveness analysis from the Chinese healthcare perspective. Cardiovasc Drugs Ther 2022;37:905-16.
68. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation 2018;138:756-66.
69. Liang Z, Chen Q, Wei R, et al. Cost-effectiveness of alirocumab for the secondary prevention of cardiovascular events after myocardial infarction in the Chinese setting. Front Pharmacol 2021;12:648244.
70. Azari S, Pourasghari H, Rezaei MA, et al. Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries. Cost Eff Resour Alloc 2025;23:68.
71. Luo B, Sun Z, Luo H. Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. Front Pharmacol 2025;16:1584612.




